<SEC-DOCUMENT>0001213900-25-003855.txt : 20250115
<SEC-HEADER>0001213900-25-003855.hdr.sgml : 20250115
<ACCEPTANCE-DATETIME>20250115162512
ACCESSION NUMBER:		0001213900-25-003855
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250115
DATE AS OF CHANGE:		20250115

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cartesian Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-89550
		FILM NUMBER:		25533203

	BUSINESS ADDRESS:	
		STREET 1:		7495 NEW HORIZON WAY
		CITY:			FREDERICK
		STATE:			MD
		ZIP:			21703
		BUSINESS PHONE:		301-348-8698

	MAIL ADDRESS:	
		STREET 1:		7495 NEW HORIZON WAY
		CITY:			FREDERICK
		STATE:			MD
		ZIP:			21703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SELECTA BIOSCIENCES INC
		DATE OF NAME CHANGE:	20090109

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SPRINGER TIMOTHY A
		CENTRAL INDEX KEY:			0001055624
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		36 WOODMAN ROAD
		CITY:			CHESTNUT HILL
		STATE:			MA
		ZIP:			02467
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001193125-19-088445</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: SPRINGER TIMOTHY A -->
          <cik>0001055624</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>19</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <dateOfEvent>01/13/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001453687</issuerCIK>
        <issuerCUSIP>816212302</issuerCUSIP>
        <issuerName>Cartesian Therapeutics, Inc.</issuerName>
        <address>
          <com:street1>7495 New Horizon Way</com:street1>
          <com:city>Frederick</com:city>
          <com:stateOrCountry>MD</com:stateOrCountry>
          <com:zipCode>21703</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Michael K. Bradshaw, Jr.</personName>
          <personPhoneNum>(202) 689-2800</personPhoneNum>
          <personAddress>
            <com:street1>Nelson Mullins Riley &amp; Scarborough LLP</com:street1>
            <com:street2>101 Constitution Avenue NW, Suite 900</com:street2>
            <com:city>Washington</com:city>
            <com:stateOrCountry>DC</com:stateOrCountry>
            <com:zipCode>20001</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001055624</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Timothy A. Springer</reportingPersonName>
        <fundType>WC</fundType>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>9555394.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>9555394.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>9555394.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>36.9</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001677543</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>TAS Partners LLC</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>563206.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>563206.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>563206.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>2.2</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Chafen Lu</reportingPersonName>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>350740.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>350740.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>350740.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>1.4</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, $0.0001 par value per share</securityTitle>
        <issuerName>Cartesian Therapeutics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>7495 New Horizon Way</com:street1>
          <com:city>Frederick</com:city>
          <com:stateOrCountry>MD</com:stateOrCountry>
          <com:zipCode>21703</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>N/A</filingPersonName>
        <principalBusinessAddress>N/A</principalBusinessAddress>
        <principalJob>N/A</principalJob>
        <hasBeenConvicted>N/A</hasBeenConvicted>
        <convictionDescription>N/A</convictionDescription>
        <citizenship>N/A</citizenship>
      </item2>
      <item3>
        <fundsSource>Item 3 of the Schedule 13D is hereby amended to be supplemented by the following: On January 2, 2025, for service on the board of directors of the Issuer, Dr. Springer was granted (i) 2,600 restricted stock units and (ii) options to purchase 7,800 Shares at an exercise price of $16.93 per share. Each restricted stock unit represents a contingent right to receive one Share, which will vest in full on January 2, 2026. The options have a term of ten years from the date of grant and vest in full on January 2, 2026. In open market purchases on January 13, 2025, Dr. Springer acquired an aggregate of 16,945 Shares at prices ranging from $16.40 to $18.00 per share for an aggregate purchase price of approximately $293,957. Dr. Springer used personal funds for such acquisitions. In open market purchases on January 14, 2025, Dr. Springer acquired an aggregate of 4,022 Shares at a price of $18.00 per share for an aggregate purchase price of approximately $72,396. Dr. Springer used personal funds for such acquisitions.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>N/A</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>Item 5 of Schedule 13D is hereby amended and restated in full as follows: The information set forth under Item 3 and the cover page of the Schedule 13D is incorporated herein by reference into this Item 5. The percentages of beneficial ownership reported in this Item 5, and on each Reporting Person's cover page to this Statement, are based on a total of 25,725,306 Shares issued and outstanding as of November 22, 2024, as reported on the Issuer's Registration Statement on Form S-3, dated December 13, 2024. All of the Share numbers reported below, and on each Reporting Person's cover page to this Statement, are as of January 15, 2025. The Reporting Persons, in the aggregate, beneficially own 9,555,394 Shares, representing approximately 36.9% of such class of securities. Dr. Springer is the beneficial owner of a total of 9,555,394 Shares, representing approximately 36.9% of the outstanding Shares and consisting of (i) 8,524,906 Shares held directly, (ii) 113,587 Shares underlying warrants exercisable within 60 days of January 15, 2025 held directly, (iii) 2,955 Shares issuable upon exercise of outstanding options exercisable within 60 days of January 15, 2025, (iv) 529,798 Shares held by TAS, (v) 33,408 Shares underlying warrants exercisable within 60 days of January 15, 2025 held by TAS, (vi) 330,695 Shares held by Dr. Lu and (vii) 20,045 Shares underlying warrants exercisable within 60 days of January 15, 2025 held by Dr. Lu. TAS is the beneficial owner of a total of 563,206 Shares, representing approximately 2.2% of the outstanding Shares and consisting of (i) 529,798 Shares and (ii) 33,408 Shares underlying warrants exercisable within 60 days of January 15, 2025. TAS holds all such Shares directly. Dr. Springer is the sole managing member of TAS. Dr. Lu is the beneficial owner of a total of 350,740 Shares, representing approximately 1.4% of the outstanding Shares and consisting of (i) 330,695 Shares held directly and (ii) 20,045 Shares underlying warrants exercisable within 60 days of January 15, 2025 held directly. Dr. Lu is the spouse of Dr. Springer.</percentageOfClassSecurities>
        <numberOfShares>Dr. Springer exercises sole voting and dispositive power over the Shares held by him directly and the Shares held by TAS. Dr. Springer disclaims beneficial ownership of the Shares held by TAS, except to the extent of his pecuniary interest therein. Dr. Lu exercises sole voting and dispositive power over the Shares held by her directly.</numberOfShares>
        <transactionDesc>The Reporting Persons have not engaged in any transactions with respect to the Shares during the 60 days before the date of this filing, except as described herein and in Item 3 of Schedule 13D.</transactionDesc>
        <listOfShareholders>No person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>N/A</contractDescription>
      </item6>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Timothy A. Springer</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Timothy A. Springer</signature>
          <title>Timothy A. Springer</title>
          <date>01/15/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>TAS Partners LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Timothy A. Springer</signature>
          <title>Timothy A. Springer/Manager</title>
          <date>01/15/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Chafen Lu</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Chafen Lu</signature>
          <title>Chafen Lu</title>
          <date>01/15/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
